Eli Lilly says oral GLP-1 Foundayo lowers predicted diabetes and heart risk
Lilly said an analysis found its oral GLP-1 Foundayo was associated with reduced predicted long-term risk of type 2 diabetes and heart disease in adults with obesity.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.